The long-term impacts of hearing loss, tinnitus and poor balance on the quality of life of people living with and beyond cancer after platinum-based chemotherapy: a literature review

Phillips, Olivia R; Baguley, David; Pearson, Stephanie; Akeroyd, Michael A.

doi:10.1007/s11764-022-01314-9

Cited by 11 publications

(8 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hair cells are the most common cochlear cell type to be affected by cisplatin, but cells of the stria vascularis, spiral ganglion neurons, and supporting cells have also been reported to suffer deleterious effects ( 5 , 6 ). Cisplatin-induced hearing loss negatively impacts an individual’s quality of life, leading to depression and social isolation ( 7 ), and impedes the development of language skills in young children treated with cisplatin ( 1 – 3 ). There is a dire clinical need to develop drugs that can protect from this highly common side effect of cisplatin treatment.…”

Section: Introductionmentioning

confidence: 99%

Dabrafenib protects from cisplatin-induced hearing loss in a clinically relevant mouse model

Ingersoll,

Lutze,

Pushpan

et al. 2023

JCI Insight

View full text Add to dashboard Cite

The widely used chemotherapy cisplatin causes permanent hearing loss in 40%–60% of patients with cancer. One drug, sodium thiosulfate, is approved by the FDA for use in pediatric patients with localized solid tumors for preventing cisplatin-induced hearing loss, but more drugs are desperately needed. Here, we tested dabrafenib, an FDA-approved BRAF kinase inhibitor and anticancer drug, in a clinically relevant multidose cisplatin mouse model. The protective effects of dabrafenib, given orally twice daily with cisplatin, were determined by functional hearing tests and cochlear outer hair cell counts. Toxicity of the drug cotreatment was evaluated, and levels of phosphorylated ERK were measured. A dabrafenib dose of 3 mg/kg BW, twice daily, in mice, was determined to be the minimum effective dose, and it is equivalent to one-tenth of the daily FDA-approved dose for human cancer treatment. The levels of hearing protection acquired, 20–25 dB at the 3 frequencies tested, in both female and male mice, persisted for 4 months after completion of treatments. Moreover, dabrafenib exhibited a good in vivo therapeutic index (> 25), protected hearing in 2 mouse strains, and diminished cisplatin-induced weight loss. This study demonstrates that dabrafenib is a promising candidate drug for protection from cisplatin-induced hearing loss.

show abstract

Section: Introductionmentioning

confidence: 99%

Dabrafenib protects from cisplatin-induced hearing loss in a clinically relevant mouse model

Ingersoll,

Lutze,

Pushpan

et al. 2023

JCI Insight

View full text Add to dashboard Cite

show abstract

“…15 High-frequency audiometry is regarded as a significant technique for identifying and monitoring hearing loss and detecting cisplatin ototoxicity, with critical frequencies of 12 kHz and 14 kHz. 5,30,31 All of this scientific evidence analysis emphasizes the significance of regular audiological monitoring during and after platinum-based treatment, and it is also encouraged to perform self-reported hearing impairment during and after chemotherapy. 15…”

Section: Discussionmentioning

confidence: 99%

Ototoxic Effects of Antineoplastic Drugs: A Systematic Review

Monica

2023

JARMHS

View full text Add to dashboard Cite

Introduction: When scientific evidence is reviewed, platinum-based chemotherapeutics are essential in cancer treatment at various levels and are the most referenced ototoxic drugs. Aim: This study aims to give scientific data based on a PRISMA systematic literature review to standardize information on the ototoxic effects of antineoplastic medicines. Methods: A combination based on the Medical Subject Heading Terms (MeSH) was utilized to choose studies. The databases Medline (Pubmed), LILACS, SciELO, SCOPUS, WEB OF SCIENCE, and BIREME were used without regard to language, period, or region. The quality of the papers was evaluated, and articles with a minimum score of 6 on the modified literature scale were included. The selected studies had descriptive, cohort, and cross-sectional designs connected to the research purpose. Results: The results of this systematic review included three papers. The ototoxicity caused by cisplatin alone ranged from 45% to 83.3%, while that caused by carboplatin usage ranged from 16.6% to 75%. The cumulative dosages of these antineoplastic drugs, both alone and in combination, varied significantly. After therapy, there were noticeable changes in hearing, particularly at high frequencies. Conclusion: Auditory alterations were observed following the administration of platinum-based antineoplastic medicines; nevertheless, there was significant variation in the frequency of ototoxicity and the cumulative dose of the drugs administered.

show abstract

“…The neurotoxicity of chronic stress from cancer and cancer treatment has been reported ( 10 ). Also, chemotherapy or radiation can result in loss of hearing and tinnitus ( 11 ). A correlation between hearing loss, depression, and cognitive decline has been reported ( 12 ), with lower cognitive performance among cancer survivors occurring up to 20 years post-treatment ( 13 ).…”

Section: Cancer Impact On Mental Healthmentioning

confidence: 99%

Role of a mental health physician in the management of oncology patients: a case vignette and the need for collaboration

Armiya'u,

Akande

2024

Front. Health Serv.

View full text Add to dashboard Cite

There is an interplay between oncology and mental health, resulting in a high prevalence of mental disorders among cancer patients. Out of the several interventions developed to target cancer specifics, collaborative care is indicated due to its efficacy. The perspective delves into the efficacy of collaborative care models, spotlighting a culturally informed strategy designed to harmonize mental and physical health interventions to bolster the overall wellbeing and resilience of individuals battling cancer. Central to our discussion is a compelling case vignette of Raliat, a patient diagnosed with ovarian cancer whose narrative exemplifies the multifaceted challenges cancer patients face, including stigma, psychological distress, and social isolation. Raliat's story illuminates the profound impact of cultural beliefs on patient experiences and the critical importance of a sensitive, holistic approach to care that respects cultural contexts. Through this lens, our analysis reveals that addressing emotional and situational stressors through collaborative care can significantly reduce oxidative stress, potentially decelerating the progression of both cancer and accompanying mental health disorders. We advocate for integrating mental health services into oncological care, drawing on the case vignette to argue for policies that facilitate such merger by employing validated collaborative care models. We conclude with a call for public education to diminish cancer stigma and improve social outcomes, emphasizing the use of a culture-informed PACER (physical, affective, cognitive, environmental, and relationship) strategy in providing comprehensive care for cancer patients and their families.

show abstract

The long-term impacts of hearing loss, tinnitus and poor balance on the quality of life of people living with and beyond cancer after platinum-based chemotherapy: a literature review

Cited by 11 publications

References 60 publications

Dabrafenib protects from cisplatin-induced hearing loss in a clinically relevant mouse model

Dabrafenib protects from cisplatin-induced hearing loss in a clinically relevant mouse model

Ototoxic Effects of Antineoplastic Drugs: A Systematic Review

Role of a mental health physician in the management of oncology patients: a case vignette and the need for collaboration

Contact Info

Product

Resources

About